Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone mood tracking may predict Post-Stroke depression

NCT ID NCT04043052

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether daily mood check-ins via a mobile app could help predict and prevent depression in people who recently had a stroke. Over 400 participants used the app for three months while researchers tracked their emotional symptoms. The goal was to see if this kind of monitoring could identify those at risk early, so doctors could step in sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ecological Momentary Assessment (EMA) via mobile app
What this could lead to
If successful, this approach could help doctors identify stroke patients at high risk for depression early and offer timely support.
What could go wrong
This is an observational study, not a treatment trial. It tests monitoring, not prevention, so it may not directly reduce depression rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

401 people

The number who actually took part.

Started

Sep 2020

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Male or Female. * Recent (≤ 15 days) clinically-symptomatic ischemic or hemorrhagic stroke documented through brain imaging (CT or MRI) or a Transient Ischemic Attack with an ABCD2 score ≥ 4. * Patient discharged to home after hospitalization in the stroke unit. * No severe neurological handicap: modified Rankin scale ≤ 3 at inclusion. * No severe cognitive impairment or dementia: MoCA ≥ 16 at inclusion. * Written informed consent by the patient. * Covered by French Social Insurance Exclusion Criteria: * Transient Non Cerebrovascular Event. * Subarachnoid hemorrhage. * Dementia syndrome or other neurologic disorder and/or severe aphasia (NIHSS item 9 ≥ 2) interfering with the completion of evaluations and the utilization of EMA. * Severe visual impairment interfering with the utilization of EMA. * Severely impaired physical and/or mental health that, according to the investigator, may affect the participant's compliance with the study * Patients with a severe substance use disorder (DSM-5 criteria) * Patients under antidepressant and/or anxiolytic and/or neuroleptic and/or mood stabilizer treatment during the month preceding inclusion * Participation in another protocol modifying the patient's follow-up status. * Pregnancy or breastfeeding * Inability to read French or to use a smartphone * Individuals under legal protection or unable to express personnally their consent * Individuals living in an area without 3G/4G internet coverage

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression depressive disorder hemorrhagic stroke ischemic stroke stroke disorder transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression Stroke

Contacts and locations

Locations

  • Assistance Publique Hopitaux de Paris - Groupe Hospitalier Paris Saint Joseph

    Paris, 75 014, France

  • CHRU de Brest

    Brest, 29 609, France

  • CHU Dijon Bourgogne

    Dijon, 21 079, France

  • CHU de Bordeaux

    Bordeaux, 33 076, France

  • CHU de Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.